<DOC>
	<DOC>NCT02259088</DOC>
	<brief_summary>Study of efficacy and safety of 0.5 mg ranibizumab in Chinese patients with diabetic macular edema (DME)</brief_summary>
	<brief_title>A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese DME Patients</brief_title>
	<detailed_description>Study to provide efficacy and safety data on 0.5 mg ranibizumab intravitreal injections compared to laser photocaagulation in Chinese patients with visual impairment due to DME. Treatment is driven by achieving vision stabilization</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Male or female Chinese patients ≥ 18 years of age with diabetes mellitus and with HbA1c ≤10.0% Stable medication for diabetes within 3 months prior to Visit 1 Visual impairment due to DME with BCVA score between 78 and 39 Stroke or myocardial infarction less than 3 months prior to screening visit Uncontrolled hypertension Active ocular infection or intraocular inflammation in any eye Treatment with any antiangiogenic drugs within 3 months prior to baseline visit in any eye Active proliferative diabetic retinopathy in study eye Use of other investigational drugs within 30 days and systemic antiVEGF drugs within 6 months prior to baseline visit Prior laser photocoagulation or intraocular procedure within 3 months prior to baseline in study eye History of intravitreal corticosteroid treatment in phakic study eye, and in aphakic or pseudophakic within 3 months prior to screening Other protocol defined inclusion /exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DME, macular edema, vision impairment, Chinese, diabetes</keyword>
</DOC>